Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610961 | 1.00 | KCNA3 (0.38) | KCNA3DRD2KDM4DAAK1PARP1 | |
| Hydrochloric Acid SCHEMBL3615584 | 0.83 | PKM (0.33) | — | |
| SCHEMBL3609928 | 0.78 | KCNH2 (0.53) | — | |
| SCHEMBL3609924 | 0.78 | KCNH2 (0.53) | — | |
| SCHEMBL3615732 | 0.78 | PKM (0.35) | — | |
| SCHEMBL3608751 | 0.76 | PKM (0.35) | DRD2 | |
| SCHEMBL3608745 | 0.76 | PKM (0.35) | DRD2 | |
| SCHEMBL3615008 | 0.75 | KCNA3 (0.36) | KCNA3DRD2KDM4DAAK1CCR5 | |
| SCHEMBL3609957 | 0.75 | KCNA3 (0.36) | KCNA3DRD2KDM4DAAK1CCR5 | |
| SCHEMBL4590167 | 0.75 | KCNA3 (0.41) | KCNA3DRD2KDM4DCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | KCNA3 3759/4885DRD2 2044/4885KDM4D 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.